Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05910164




Registration number
NCT05910164
Ethics application status
Date submitted
9/06/2023
Date registered
18/06/2023
Date last updated
1/10/2024

Titles & IDs
Public title
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Scientific title
Single-center, Randomized, Crossover Clinical Study to Assess Patient Preference Between the Use of a Prefilled Syringe or a Prefilled Pen Device for Pegfilgrastim Administration (PELGRAZ) as Primary Prophylaxis of Chemotherapy-related Neutropenia
Secondary ID [1] 0 0
ID RCB: 2022-A01465-38
Secondary ID [2] 0 0
IR-2022/0011
Universal Trial Number (UTN)
Trial acronym
PELGRAZ
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Patient Preference 0 0
Febrile Neutropenia, Drug-Induced 0 0
Patient Satisfaction 0 0
Condition category
Condition code
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Devices - PELGRAZ prefilled syringe or PELGRAZ prefilled pen

A) administration starting with prefilled syringe - - Group A = Phase 1 then phases 2, 3, 4

The study protocol consists of 4 different stages

* Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)
* Phase 2: pen injection guided (thanks to the detailed information) by the IDE
* Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase
* Phase 4: injection by pen in complete autonomy, patient alone

B) administration starting with prefilled pen - - Group B = Phase 2, 3, 4 then phase 1

The study protocol consists of 4 different stages

* Phase 1: injection by pre-filled syringe by a state-certified nurse (IDE)
* Phase 2: pen injection guided (thanks to the detailed information) by the IDE
* Phase 3: injection by pen in autonomy supervised by the IDE (can only interfere in case of non-compliance with the injection protocol) = Learning phase
* Phase 4: injection by pen in complete autonomy, patient alone


Treatment: Devices: PELGRAZ prefilled syringe or PELGRAZ prefilled pen
PELGRAZ prefilled syringe or PELGRAZ prefilled pen https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
questionnaire
Timepoint [1] 0 0
120 days
Secondary outcome [1] 0 0
questionnaire, specific questions
Timepoint [1] 0 0
120 days

Eligibility
Key inclusion criteria
* 18 years old and older
* Patients with solid tumors, Hodgkin's lymphoma, non-Hodgkin's lymphoma and receiving myelosuppressive chemotherapy with a risk of NF of 10-20% (individual risk factors), or = 20% (primary prevention of neutropenia) and receiving PELGRAZ ® in accordance with CPR
* Prediction of the risk of NF without filgrastim or pegfilgrastim determined according to the recommendations of the EORTC
* ECOG = 2
* Free and informed consent obtained
* Patient affiliated to a social security system or beneficiary of such a scheme
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnancy
* Breastfeeding
* Patients receiving concurrent radiotherapy
* Second cancer treated with chemotherapy
* Participation in any other clinical trial within 30 days prior to recruitment
* Concomitant myelosuppressive therapy, e.g. ex. immunosuppressive therapy
* History of severe hypersensitivity reaction to drugs intended for use and/or drugs derived from E. coli

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/06/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/10/2024
Actual
Sample size
Target
Accrual to date
Final
150
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
France
State/province [1] 0 0
Ile-de-France

Funding & Sponsors
Primary sponsor type
Other
Name
Institut Rafael
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Alain TOLEDANO, MD
Address 0 0
Institut Rafael
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05910164